The trajectory of companies tied to Sildenafil's past presents a intricate investment scenario . While the initial surge generated substantial gains, generic copies have significantly eroded sales . Investing in related pharmaceutical firms now requires a careful assessment of proprietary safeguards, evolving patient changes, and the possibility fo